BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson's Disease to AbbVie After Receiving Clearance

STOCKHOLM, Dec. 14, 2018 -- (Healthcare Sales & Marketing Network) -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic and its partner AbbVie (NYSE: ABBV) have received U.S. Federal Trade Commission (FTC) clearance to license ... Biopharmaceuticals, Neurology, Licensing BioArctic, AbbVie, alpha-synuclein, Parkinson's disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news